Article Text

Download PDFPDF
Sensitivity to cisplatin determined by the histoculture drug response assay and clinical response of endometrial cancer
  1. M. Kanasugi*,
  2. D. Aoki*,
  3. N. Suzuki*,
  4. N. Susumu*,
  5. S. Nakata*,
  6. M. Horiuchi*,
  7. Y. Udagawa and
  8. S. Nozawa*
  1. *Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan
  2. Department of Obstetrics and Gynecology, Fujita Health University School of Medicine, Aichi, Japan
  1. Address correspondence and reprint requests to: Daisuke Aoki, MD, Department of Obstetrics and Gynecology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Email: aoki{at}


This study investigated the value of the in vitro histoculture drug response assay (HDRA) for predicting the efficacy of chemotherapy in patients with endometrial cancer. Specimens were obtained from 115 patients with endometrial cancer treated at Keio University Hospital between 1994 and 2002. Tumor fragments were cultured on collagen sponge gel with cisplatin for 7 days, and cell viability was assessed. The cutoff value of the 50% inhibitory concentration of cisplatin was set at 23 μg/mL. Sensitivity of stage III or IV disease to chemotherapy was investigated, and differences of 5-year progression-free survival between patients with sensitive and resistant tumors were evaluated by the Kaplan–Meier method. Tumors were evaluable in 93.0% of patients (107/115). Among 38 patients in stages III or IV, 23 received chemotherapy containing cisplatin. Seven sensitive tumors did not recur, while recurrence/progression occurred within 6 months in 8/16 patients with tumors showing low sensitivity. Among stages III and IV patients, there was a significant difference of 5-year progression-free survival (P < 0.05) between those with tumors showing high or low sensitivity. Accordingly, the HDRA may predict the efficacy of chemotherapy for endometrial cancer.

  • cisplatin
  • endometrial cancer
  • histoculture drug response assay

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.